Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 200 of 672 entries
View as:

Sofosbuvir + Ribavirin for 12 Weeks in Subjects With Chronic Genotype 2 or 3 Hepatitis C Infection Who Are Interferon Intolerant, Interferon Ineligible or Unwilling to Take Interferon

Phase: N/A Priority: Normal
NCT ID: NCT01542788 Org: User:
Start: 03/31/12 End: 02/28/13 Due: 02/28/14

Andecaliximab as Add-On Therapy to a Tumor Necrosis Factor Inhibitor and Methotrexate Regimen in Adults With Moderately to Severely Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT02862574 Org: User:
Start: 12/15/16 End: 08/07/17 Due: 08/07/18

Phase II Study of IMMU-132 Alone or in Combination With Carboplatin in Patients With Triple-Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02161679 Org: User:
Start: 08/31/16 End: 08/31/16 Due: 08/31/17

Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT03053050 Org: User:
Start: 02/13/17 End: 06/19/19 Due: 06/19/20

Efficacy of Sofosbuvir With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant

Phase: N/A Priority: Normal
NCT ID: NCT01559844 Org: User:
Start: 03/31/12 End: 10/31/14 Due: 10/31/15

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26)

Phase: N/A Priority: Normal
NCT ID: NCT06486441 Org: User:
Start: 08/28/24 End: 06/30/29 Due: 06/30/30

Study to Evaluate Switching From a Regimen Consisting of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF) Fixed Dose Combination (FDC) to Emtricitabine/Rilpivirine/Tenofovir Alafenamide (FTC/RPV/TAF) FDC in Virologically-Suppressed, HIV-1 Infected Adults

Phase: N/A Priority: Normal
NCT ID: NCT02345226 Org: User:
Start: 01/26/15 End: 01/02/19 Due: 01/02/20

Safety Study of 90Y-hMN14 to Treat Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00041639 Org: User:
Start: 01/31/00 End: 12/31/03 Due: 12/31/04

Study of GS-3242 in Participants With HIV-1

Phase: N/A Priority: Normal
NCT ID: NCT07001319 Org: User:
Start: 06/30/25 End: 02/28/27 Due: 02/28/28

A Phase 1 Study to Characterize the Effect of GS-5737 Enhancement of Mucociliary Clearance (MCC) in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01793649 Org: User:
Start: 10/31/12 End: 06/30/13 Due: 06/30/14

Phase I/II Study of Different Doses and Dose Schedules of Milatuzumab (hLL1) in CLL

Phase: N/A Priority: Normal
NCT ID: NCT00603668 Org: User:
Start: 08/31/08 End: 02/28/13 Due: 02/28/14

Safety, Tolerability and Antiviral Activity of Selgantolimod in Virally-Suppressed Participants With Chronic Hepatitis B

Phase: N/A Priority: Normal
NCT ID: NCT03491553 Org: User:
Start: 04/06/18 End: 08/10/20 Due: 08/10/21

ADVANCE MPI 2: Study of Regadenoson Versus Adenoscan® in Patients Undergoing Myocardial Perfusion Imaging (MPI)

Phase: N/A Priority: Normal
NCT ID: NCT00208312 Org: User:
Start: 04/30/04 End: 06/30/05 Due: 06/30/06

Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL

Phase: N/A Priority: Normal
NCT ID: NCT00546793 Org: User:
Start: 01/31/08 End: 03/31/13 Due: 03/31/14

Sofosbuvir Plus Ribavirin Administered for Either 12 or 24 Weeks in Treatment-Naive and Treatment-Experienced Egyptian Adults With Chronic Genotype 4 Hepatitis C Virus (HCV) Infection

Phase: N/A Priority: Normal
NCT ID: NCT01838590 Org: User:
Start: 03/31/13 End: 08/31/14 Due: 08/31/15

Study to Evaluate the Efficacy, Safety, and Tolerability of Tirabrutinib in Participants With Antihistamine-Resistant Chronic Spontaneous Urticaria

Phase: N/A Priority: Normal
NCT ID: NCT04827589 Org: User:
Start: 07/31/21 End: 09/30/22 Due: 09/30/23

Dose Escalation and Dose Expansion Study of Tirabrutinib in Combination With Other Targeted Anti-cancer Therapies in Adults With B-cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02457598 Org: User:
Start: 06/16/15 End: 09/25/24 Due: 09/25/25

Phase I/II Study of hLL1-DOX in Relapsed NHL and CLL

Phase: N/A Priority: Normal
NCT ID: NCT01585688 Org: User:
Start: 08/31/12 End: 10/31/17 Due: 10/31/18

Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF)

Phase: N/A Priority: Normal
NCT ID: NCT01769196 Org: User:
Start: 01/31/13 End: 02/23/16 Due: 02/23/17

International Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Cystic Fibrosis Patients With P. Aeruginosa

Phase: N/A Priority: Normal
NCT ID: NCT00112359 Org: User:
Start: 05/31/05 End: 04/30/07 Due: 04/30/08

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

Phase: N/A Priority: Normal
NCT ID: NCT00036634 Org: User:
Start: 03/31/02 End: 02/28/03 Due: 02/28/04

Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection

Phase: N/A Priority: Normal
NCT ID: NCT01965535 Org: User:
Start: 10/31/13 End: 11/30/14 Due: 11/30/15

Safety and Efficacy Study of Metaglidasen in Type 2 Diabetes in Patients Suboptimally Controlled on Insulin

Phase: N/A Priority: Normal
NCT ID: NCT00353587 Org: User:
Start: 05/31/06 End: 11/30/07 Due: 11/30/08

Selonsertib in Combination With Prednisolone Versus Prednisolone Alone in Participants With Severe Alcoholic Hepatitis (AH)

Phase: N/A Priority: Normal
NCT ID: NCT02854631 Org: User:
Start: 09/01/16 End: 05/31/18 Due: 05/31/19

Efficacy and Safety of Tenofovir Alafenamide (TAF) Versus Tenofovir Disoproxil Fumarate (TDF)-Containing Regimens in Participants With Chronic Hepatitis B Virus (HBV) Infection and Stage 2 or Greater Chronic Kidney Disease Who Have Received a Liver Transplant

Phase: N/A Priority: Normal
NCT ID: NCT02862548 Org: User:
Start: 09/16/16 End: 05/05/21 Due: 05/05/22